Results 131 to 140 of about 10,698,899 (242)

Subcutaneous Allergen Immunotherapy With Thermosensitive Hydrogel and Recombinant Birch Pollen Allergen Variant, a Randomised Controlled Trial

open access: yesClinical &Experimental Allergy, EarlyView.
A Phase 1, randomised, placebo‐controlled, dose‐escalation trial was performed with 30 birch pollen allergic subjects treated with DM‐101PX, that contains a recombinant hypoallergenic variant of Bet v 1 formulated with poloxamer 338 thermosensitive hydrogel.
Anna Nilson   +14 more
wiley   +1 more source

Charting the course of Sjögren's disease: A historical analysis of scientific progress

open access: yesEuropean Journal of Oral Sciences, EarlyView.
Abstract Sjögren's disease (SjD) bears the name of the Swedish ophthalmologist Henrik Sjögren. His 1933 doctoral thesis on keratoconjunctivitis sicca ignited interest, yet much remains under debate. SjD is an autoimmune disorder that primarily affects the exocrine glands, particularly the salivary and lacrimal glands, leading to a dryness of the eyes ...
Diego Ustárroz Cantali   +3 more
wiley   +1 more source

Cutaneous lymphomas – an update

open access: yesHistopathology, EarlyView.
Primary cutaneous lymphomas and lymphoproliferative disorders are defined by integrated clinical, histopathological, immunophenotypic and genetic features as diagnostic criteria also in the 5th edition of the WHO classification of haematolymphoid tumors.
Werner Kempf, Christina Mitteldorf
wiley   +1 more source

IgG4-Related Sclerosing Cholangitis in Europe

open access: yes, 2018
IgG4-Related sclerosing cholangitis in ...
Giulia De Marchi   +7 more
core   +1 more source

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern   +14 more
wiley   +1 more source

IgG4-Related Diseases-Continues To Be a Cancer Mimicker. [PDF]

open access: yesCureus, 2020
Sodavarapu S   +4 more
europepmc   +1 more source

AQP1 Corrects Acinar Cells’ Secretion Deficits in Sjögren's Disease

open access: yesOral Diseases, EarlyView.
ABSTRACT Introduction Sjögren's disease (SjD) is a systemic autoimmune disease characterized by dry mouth, dry eyes, and profound fatigue. Preclinical studies suggest that AQP1 gene expression in salivary glands corrects salivary hypofunction in preclinical and clinical studies of radiation‐induced xerostomia and improves salivary and lacrimal function
Paola Perez   +12 more
wiley   +1 more source

The role of acquired host immunity in periodontal diseases

open access: yesPeriodontology 2000, EarlyView.
Abstract The aim of this narrative review is to relate the contribution of European researchers to the complex topic of the host immune system in periodontal disease, focusing on acquired immunity. Other chapters in this volume will address the genetics and autoantibody responses and other forms of immunity to periodontal disease.
Denis F. Kinane   +2 more
wiley   +1 more source

Pretransfusion testing interference profile of IMC‐002: A novel anti‐CD47 monoclonal antibody engineered for minimized red cell binding

open access: yesTransfusion, EarlyView.
Abstract Background CD47‐targeted agents can interfere with pretransfusion testing due to CD47 expression on red blood cells (RBCs). IMC‐002 is a novel anti‐CD47 human IgG4 monoclonal antibody engineered to minimize RBC binding; however, its interference profile during pretransfusion testing remains poorly characterized.
Tae‐Shin Kim   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy